deltatrials
Unknown PHASE2 NCT00002454

Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx

Sponsor: University of Medicine and Dentistry of New Jersey

Conditions Precancerous Condition
Interventions autologous tumor cell vaccine
Updated 5 times since 2017 Last updated: Jul 23, 2011 Started: Dec 31, 1971

This PHASE2 trial investigates Precancerous Condition and is currently ongoing. University of Medicine and Dentistry of New Jersey leads this study, which shows 5 recorded versions since 1971 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Dec 1971

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Medicine and Dentistry of New Jersey
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Newark, United States